<code id='D973589D10'></code><style id='D973589D10'></style>
    • <acronym id='D973589D10'></acronym>
      <center id='D973589D10'><center id='D973589D10'><tfoot id='D973589D10'></tfoot></center><abbr id='D973589D10'><dir id='D973589D10'><tfoot id='D973589D10'></tfoot><noframes id='D973589D10'>

    • <optgroup id='D973589D10'><strike id='D973589D10'><sup id='D973589D10'></sup></strike><code id='D973589D10'></code></optgroup>
        1. <b id='D973589D10'><label id='D973589D10'><select id='D973589D10'><dt id='D973589D10'><span id='D973589D10'></span></dt></select></label></b><u id='D973589D10'></u>
          <i id='D973589D10'><strike id='D973589D10'><tt id='D973589D10'><pre id='D973589D10'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:5
          Scanned cerebellum of a mouse brain, affected by Niemann-Pick Type C, shown in pink and teal — biotech coverage from STAT
          The cerebellum of a mouse brain affected by Niemann-Pick Type C. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

          About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo drug, probing its effects on people with balance disorders, when she thought of another, very sick group of patients. 

          A graduate student and medical resident at the German Center for Vertigo and Balance Disorders, in Munich, Bremova-Ertl often saw patients with Niemann-Pick Type C, a rare, genetic disease that slowly kills neurons. 

          advertisement

          NPC has a range of manifestations. When symptoms appear in early childhood, it is often fatal before adulthood. When it manifests  later, it can be milder. But it’s always degenerative and leads to a cluster of challenges: cognitive decline, difficulty with speech and swallowing, enlarged liver, low muscle tone, and, notably, difficulty with balance and muscle control. Researchers and a fervent group of parents were working to develop medicines, but little had yet worked. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          I learned firsthand about improving diversity in clinical trials
          I learned firsthand about improving diversity in clinical trials

          Asthebiopharmaceuticalindustryplacesincreasedemphasisonimprovingthediversityofparticipantsinclinical

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Vir antibody drug aimed at influenza A fails in clinical trial

          F.A.Murphy/CDCVirBiotechnologysaidThursdaythatalong-actingantibodydrugdesignedtoprotecthealthyindivi